XKRX
253840
Market cap51mUSD
Oct 08, Last price
4,545.00KRW
1D
-7.06%
1Q
19.13%
IPO
-30.08%
Name
SugenTech Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sugentech Inc., a South Korean firm, develops and markets advanced in-vitro diagnostic (IVD) systems and products worldwide. Their solutions integrate biotechnology, information technology, and nanotechnology. The company's diverse portfolio features sophisticated Multiplex BLOT disease diagnostic platforms, including automated immunoblot processors and molecular diagnostic tools, alongside various test kits. They also offer a range of convenient self-testing products, such as digital ovulation, pregnancy, and early pregnancy detection kits, as well as mobile testing options. Additionally, Sugentech provides point-of-care (POC) analyzers and tests for a broad spectrum of conditions, from infectious diseases like M.tuberculosis, M.bovis, SARS-CoV-2 (antibodies and antigens), and influenza A/B, to critical biomarkers such as CRP/hsCRP/dualCRP, procalcitonin, troponin I, hemoglobinA1c, and human chorionic gonadotropin. Founded in 2011, the company, originally named Accugen Healthcare, Inc., adopted its current name, Sugentech Inc., in October 2013 and is headquartered in Daejeon.
Key people
Mi Jin Son
Chief Executive Officer, Director
Hae Gwon Lee
Chief Financial Officer, Managing Director
Su Jin Gu
Managing Director
Eun Gyeong Kim
Assistant Managing Director
Seung Beom Yoo
Chief Technology Officer, Vice President, Director
Gang Hui Cho
Non-Executive Independent Director · since 2024
Gang Min Huh
Non-Executive Independent Director
Jae Hong Jeon
Non-Executive Independent Director
Non-Executive Independent Director · since 2025
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||